## Contents

1 Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidney Disease .......................... 1
   Tevfik Eeder

2 Lipid Nephrotoxicity: New Concept for an Old Disease ................. 9
   Xiong Zhong Ruan, Zac Varghese, and John Moorhead

3 Hyperlipidemia as a Risk Factor for Progression of CKD in Nondiabetics ................................................................. 27
   Agata Kujawa-Szewieczek, Grzegorz Piecha, and Andrzej Więcek

4 How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly ............................................................... 45
   Faruk Turgut, Ihsan Ustun, and Cumali Gökce

5 CVD in CKD: Focus on the Dyslipidemia Problem .......................... 67
   Theodoros Kassimatis and David Goldsmith

6 The CKD Patient with Dyslipidemia ............................................. 93
   Valentina Batini and Stefano Bianchi

7 Review of Clinical Trials Pertaining to Dyslipidemias in CKD ........ 111
   Markus P. Schneider and Kai-Uwe Eckardt

8 Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease ............................................................ 129
   Ali Olyaei, Jessica Lassiter, and Edgar V. Lerma

9 Non-statin Therapies for CKD with Dyslipidemia ......................... 153
   Istvan Mucsi

10 Dyslipidemia in Dialysis ............................................................ 179
    Yalcin Solak and Halil Zeki Tonbul
11 Dyslipidemia in the Kidney Transplant Patient ........................................... 203
Rajan Kantilal Patel and Alan G. Jardine

12 Dyslipidemia in Nephrotic Syndrome ....................................................... 213
Minso Kim and Howard Trachtman

13 Dyslipidemias in the Pediatric Chronic Kidney Disease Patient ................... 231
Zeynep Birsin Özçakar and Fatoş Yalçınkaya

14 Dyslipidemias in the Geriatric Chronic Kidney Disease Patients ............... 255
Zeynel Abidin Ozturk and Zekeriya Ulger

15 Apheresis Methods in Hyperlipidemias .................................................... 269
Serdar Sivgin

16 Review of Current Guidelines: National Cholesterol Education Program and Kidney Disease Outcomes Quality Initiative as They Apply to CKD with Dyslipidemias ......................... 287
Baris Afsar

Index ................................................................................................................. 301